Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity.


Journal

Microbiome
ISSN: 2049-2618
Titre abrégé: Microbiome
Pays: England
ID NLM: 101615147

Informations de publication

Date de publication:
14 04 2021
Historique:
received: 28 08 2020
accepted: 02 02 2021
entrez: 15 4 2021
pubmed: 16 4 2021
medline: 28 4 2021
Statut: epublish

Résumé

Coronavirus disease 2019 (COVID-19) caused by the enveloped RNA virus SARS-CoV-2 primarily affects the respiratory and gastrointestinal tracts. SARS-CoV-2 was isolated from fecal samples, and active viral replication was reported in human intestinal cells. The human gut also harbors an enormous amount of resident viruses (collectively known as the virome) that play a role in regulating host immunity and disease pathophysiology. Understanding gut virome perturbation that underlies SARS-CoV-2 infection and severity is an unmet need. We enrolled 98 COVID-19 patients with varying disease severity (3 asymptomatic, 53 mild, 34 moderate, 5 severe, 3 critical) and 78 non-COVID-19 controls matched for gender and co-morbidities. All subjects had fecal specimens sampled at inclusion. Blood specimens were collected for COVID-19 patients at admission to test for inflammatory markers and white cell counts. Among COVID-19 cases, 37 (38%) patients had serial fecal samples collected 2 to 3 times per week from time of hospitalization until after discharge. Using shotgun metagenomics sequencing, we sequenced and profiled the fecal RNA and DNA virome. We investigated alterations and longitudinal dynamics of the gut virome in association with disease severity and blood parameters. Patients with COVID-19 showed underrepresentation of Pepper mild mottle virus (RNA virus) and multiple bacteriophage lineages (DNA viruses) and enrichment of environment-derived eukaryotic DNA viruses in fecal samples, compared to non-COVID-19 subjects. Such gut virome alterations persisted up to 30 days after disease resolution. Fecal virome in SARS-CoV-2 infection harbored more stress-, inflammation-, and virulence-associated gene encoding capacities including those pertaining to bacteriophage integration, DNA repair, and metabolism and virulence associated with their bacterial host. Baseline fecal abundance of 10 virus species (1 RNA virus, pepper chlorotic spot virus, and 9 DNA virus species) inversely correlated with disease COVID-19 severity. These viruses inversely correlated with blood levels of pro-inflammatory proteins, white cells, and neutrophils. Among the 10 COVID-19 severity-associated DNA virus species, 4 showed inverse correlation with age; 5 showed persistent lower abundance both during disease course and after disease resolution relative to non-COVID-19 subjects. Both enteric RNA and DNA virome in COVID-19 patients were different from non-COVID-19 subjects, which persisted after disease resolution of COVID-19. Gut virome may calibrate host immunity and regulate severity to SARS-CoV-2 infection. Our observation that gut viruses inversely correlated with both severity of COVID-19 and host age may partly explain that older subjects are prone to severe and worse COVID-19 outcomes. Altogether, our data highlight the importance of human gut virome in severity and potentially therapeutics of COVID-19. Video Abstract.

Sections du résumé

BACKGROUND
Coronavirus disease 2019 (COVID-19) caused by the enveloped RNA virus SARS-CoV-2 primarily affects the respiratory and gastrointestinal tracts. SARS-CoV-2 was isolated from fecal samples, and active viral replication was reported in human intestinal cells. The human gut also harbors an enormous amount of resident viruses (collectively known as the virome) that play a role in regulating host immunity and disease pathophysiology. Understanding gut virome perturbation that underlies SARS-CoV-2 infection and severity is an unmet need.
METHODS
We enrolled 98 COVID-19 patients with varying disease severity (3 asymptomatic, 53 mild, 34 moderate, 5 severe, 3 critical) and 78 non-COVID-19 controls matched for gender and co-morbidities. All subjects had fecal specimens sampled at inclusion. Blood specimens were collected for COVID-19 patients at admission to test for inflammatory markers and white cell counts. Among COVID-19 cases, 37 (38%) patients had serial fecal samples collected 2 to 3 times per week from time of hospitalization until after discharge. Using shotgun metagenomics sequencing, we sequenced and profiled the fecal RNA and DNA virome. We investigated alterations and longitudinal dynamics of the gut virome in association with disease severity and blood parameters.
RESULTS
Patients with COVID-19 showed underrepresentation of Pepper mild mottle virus (RNA virus) and multiple bacteriophage lineages (DNA viruses) and enrichment of environment-derived eukaryotic DNA viruses in fecal samples, compared to non-COVID-19 subjects. Such gut virome alterations persisted up to 30 days after disease resolution. Fecal virome in SARS-CoV-2 infection harbored more stress-, inflammation-, and virulence-associated gene encoding capacities including those pertaining to bacteriophage integration, DNA repair, and metabolism and virulence associated with their bacterial host. Baseline fecal abundance of 10 virus species (1 RNA virus, pepper chlorotic spot virus, and 9 DNA virus species) inversely correlated with disease COVID-19 severity. These viruses inversely correlated with blood levels of pro-inflammatory proteins, white cells, and neutrophils. Among the 10 COVID-19 severity-associated DNA virus species, 4 showed inverse correlation with age; 5 showed persistent lower abundance both during disease course and after disease resolution relative to non-COVID-19 subjects.
CONCLUSIONS
Both enteric RNA and DNA virome in COVID-19 patients were different from non-COVID-19 subjects, which persisted after disease resolution of COVID-19. Gut virome may calibrate host immunity and regulate severity to SARS-CoV-2 infection. Our observation that gut viruses inversely correlated with both severity of COVID-19 and host age may partly explain that older subjects are prone to severe and worse COVID-19 outcomes. Altogether, our data highlight the importance of human gut virome in severity and potentially therapeutics of COVID-19. Video Abstract.

Identifiants

pubmed: 33853691
doi: 10.1186/s40168-021-01008-x
pii: 10.1186/s40168-021-01008-x
pmc: PMC8044506
doi:

Substances chimiques

RNA 63231-63-0
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

91

Références

Cell Host Microbe. 2019 Feb 13;25(2):285-299.e8
pubmed: 30763538
Cell Host Microbe. 2016 May 11;19(5):713-9
pubmed: 27107939
Gut. 2020 Jun;69(6):1141-1143
pubmed: 32102928
J Immunol. 2018 Sep 15;201(6):1615-1624
pubmed: 30181300
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
Nat Metab. 2020 Jul;2(7):572-585
pubmed: 32694793
Viruses. 2015 Apr 20;7(4):2074-98
pubmed: 25903834
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Clin Infect Dis. 2020 Jul 28;71(15):706-712
pubmed: 32109279
PLoS Biol. 2006 Jan;4(1):e3
pubmed: 16336043
Cell. 2003 Apr 18;113(2):171-82
pubmed: 12705866
Cell. 2015 Jan 15;160(1-2):37-47
pubmed: 25594173
Mol Gen Genet. 1977 Apr 29;152(3):205-10
pubmed: 327276
Nat Microbiol. 2017 Jul 10;2:17112
pubmed: 28692019
Gastroenterology. 2020 Oct;159(4):1302-1310.e5
pubmed: 32598884
Sci Adv. 2020 Apr 29;6(18):eabc1518
pubmed: 32494691
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
PLoS One. 2010 Apr 06;5(4):e10041
pubmed: 20386604
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Gut. 2019 Jul;68(7):1169-1179
pubmed: 30842211
Genome Biol. 2014 Mar 03;15(3):R46
pubmed: 24580807
Med Mal Infect. 2020 Jun;50(4):332-334
pubmed: 32243911
Curr Opin Virol. 2011 Oct;1(4):298-303
pubmed: 22034588
Nat Rev Immunol. 2008 Nov;8(11):889-95
pubmed: 18927577
Nat Rev Microbiol. 2017 Apr;15(4):243-254
pubmed: 28239153
Clin Chim Acta. 2020 Aug;507:174-180
pubmed: 32339487
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Turk J Med Sci. 2020 Apr 17;50(SI-1):620-632
pubmed: 32299202
Nanoscale. 2018 Jan 25;10(4):1667-1679
pubmed: 29231944
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Cell Host Microbe. 2019 Oct 9;26(4):527-541.e5
pubmed: 31600503
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
Gut. 2021 Feb;70(2):276-284
pubmed: 32690600
Cell Host Microbe. 2019 Dec 11;26(6):764-778.e5
pubmed: 31757768
Nat Commun. 2019 Feb 14;10(1):752
pubmed: 30765709
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Cell Host Microbe. 2020 Nov 11;28(5):741-751.e4
pubmed: 32910902
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2192-7
pubmed: 10051617
JAMA. 2020 Nov 3;324(17):1723-1724
pubmed: 33031513
Cell. 2014 Mar 27;157(1):142-50
pubmed: 24679532
Front Microbiol. 2018 Apr 23;9:749
pubmed: 29740407
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613
J Bacteriol. 2002 Sep;184(17):4891-905
pubmed: 12169615

Auteurs

Tao Zuo (T)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
State Key Laboratory for Digestive disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Qin Liu (Q)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
State Key Laboratory for Digestive disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Microbiota I-Center (MagIC), The Chinese University of Hong Kong, Hong Kong, China.

Fen Zhang (F)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
State Key Laboratory for Digestive disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Microbiota I-Center (MagIC), The Chinese University of Hong Kong, Hong Kong, China.

Yun Kit Yeoh (YK)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Microbiota I-Center (MagIC), The Chinese University of Hong Kong, Hong Kong, China.
Department of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Yating Wan (Y)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
State Key Laboratory for Digestive disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Microbiota I-Center (MagIC), The Chinese University of Hong Kong, Hong Kong, China.

Hui Zhan (H)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
State Key Laboratory for Digestive disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Microbiota I-Center (MagIC), The Chinese University of Hong Kong, Hong Kong, China.

Grace C Y Lui (GCY)

Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Zigui Chen (Z)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Amy Y L Li (AYL)

Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Chun Pan Cheung (CP)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
State Key Laboratory for Digestive disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Microbiota I-Center (MagIC), The Chinese University of Hong Kong, Hong Kong, China.

Nan Chen (N)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
State Key Laboratory for Digestive disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Wenqi Lv (W)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
State Key Laboratory for Digestive disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Microbiota I-Center (MagIC), The Chinese University of Hong Kong, Hong Kong, China.

Rita W Y Ng (RWY)

Department of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Eugene Y K Tso (EYK)

Department of Medicine and Geriatrics, United Christian Hospital, Hong Kong, China.

Kitty S C Fung (KSC)

Department of Pathology, United Christian Hospital, Hong Kong, China.

Veronica Chan (V)

Department of Medicine and Geriatrics, United Christian Hospital, Hong Kong, China.

Lowell Ling (L)

Department of Anaesthesia and Intensive Care, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Gavin Joynt (G)

Department of Anaesthesia and Intensive Care, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

David S C Hui (DSC)

Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Francis K L Chan (FKL)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
State Key Laboratory for Digestive disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Microbiota I-Center (MagIC), The Chinese University of Hong Kong, Hong Kong, China.

Paul K S Chan (PKS)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Department of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Siew C Ng (SC)

Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China. siewchienng@cuhk.edu.hk.
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, Hong Kong, China. siewchienng@cuhk.edu.hk.
State Key Laboratory for Digestive disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China. siewchienng@cuhk.edu.hk.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China. siewchienng@cuhk.edu.hk.
Microbiota I-Center (MagIC), The Chinese University of Hong Kong, Hong Kong, China. siewchienng@cuhk.edu.hk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH